Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13212686 | 0.84 | KMT2A (0.36) | BRD4KMT2A | |
| SCHEMBL12404796 | 0.78 | BRD4 (0.60) | BRD4ALDH1A1 | |
| SCHEMBL3501053 | 0.77 | TSHR (0.45) | TSHRALDH1A1MAPK1MEN1MAPT | |
| SCHEMBL12404787 | 0.75 | HDAC1 (0.47) | BRD4 | |
| SCHEMBL12404781 | 0.70 | BRD4 (0.35) | BRD4ALDH1A1MEN1KMT2A | |
| SCHEMBL12405196 | 0.68 | BRD4 (0.38) | BRD4KMT2A | |
| SCHEMBL12359549 | 0.68 | EPHX2 (0.47) | TSHRMEN1KMT2A | |
| SCHEMBL12405193 | 0.66 | CYP3A4 (0.37) | BRD4TSHRALDH1A1MAPT | |
| SCHEMBL30379345 | 0.65 | SIRT1 (0.43) | BRD4TSHRALDH1A1MAPK1MEN1 | |
| SCHEMBL26091208 | 0.65 | SIRT1 (0.43) | BRD4TSHRALDH1A1MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985748-B2 | ALPHA2C adrenoreceptor agonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985748-B2 | ALPHA2C adrenoreceptor agonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20100173823-A1 | ALPHA2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2010-07-08 | — | — | US | disclosed |
| US-20100173823-A1 | ALPHA2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173823-A1 | ALPHA2C ADRENORECEPTOR AGONISTS | ADRA2C, ADRB2, ADRA2A | BRD4 1579/4885TSHR 245/4885ALDH1A1 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.